
'Grown Up' Drug Maker Shanghai Henlius Targets Global Fight To Beat Cancer
Drug maker Shanghai Henlius traces its history to 1992, when four ambitious young entrepreneurs formed Fosun Group to seize burgeoning opportunities in the early days of China's economic reforms. Eyeing the rapidly growing country's healthcare needs, it created Fosun Pharmaceuticals in 2004.
Shanghai Henlius was founded by Fosun Pharma and two scientists in 2010 to develop and deliver biosimilars -- relatively affordable versions of brand-name drugs innovated elsewhere. Evolving from a research-based biotech company to more of a biopharmaceutical company that creates its own final products, Henlius went public at the Hong Kong Stock Exchange in 2019.
Fifteen years after its birth, Henlius has 'grown up,' CEO Jason Zhu recently told Forbes China. Helped particularly by an expanding portfolio of cancer drugs, Henlius's revenue climbed 6% from 2023 last year to reach a record 5.7 billion yuan. Net income in 2024 climbed by half to 820.5 million yuan – the company's second straight year of profits. Last year's total revenue was more than 60 times Henlius's total of 90 million yuan, or $12.6 million, recorded during the year of its IPO; net profit over that same period reversed from a loss of 874.8 million yuan in 2009. To date, Henlius has had six products approved for marketing in China, along with four globally. For its part, Fosun Group has evolved into a global consumer-oriented group with a strong presence in the biopharmaceutical industry.
Henlius has succeeded by combining short- and long-cycle investments, Zhu said. The Shanghai-based company is trying to balance 'low-risk, high-certainty' risks with 'high-risk, high-reward' innovation such as in antibody-drug conjugates; the latter offer exponential returns from bring high costs and complexity, he said. Henlius's success has been borne out at the stock market. Shares have recouped ground lost during Covid, and more than doubled in the past year to as much as HK$51.5.
Zhu sees more growth ahead, based on a pipeline of cancer and ophthalmologic drugs, as well as expanded international partnerships. The company 'is committed to achieving a balanced revenue structure between domestic and global markets,' Zhu said. That suggests it has a lot of room to grow: international revenue was only 14% of its total in 2024. Henlius's overseas business goal is supported by accelerating product launches in the EU, U.S., Latin America and the Asia-Pacific, expanded licensing agreements; and deepening collaboration with global partners, he said.
Henlius's gains to date are part of a boom in China's home pharmaceutical market. Spending in the world's second-most populous nation is expected to reach $126.6 billion in 2023, growing 7.8% annually, according to figures released in late 2024. Growing business helped more than four dozen mainland China healthcare industry leaders make the 2025 Forbes Billionaires List.
Zhu got into medicine based on an early interest in science, a shortage of physicians in China, and a belief that doctors can 'change the course of a person's life.' He graduated from Shanghai Medical College in July 2001, and went on to work as an internal medicine physician in Huashan Hospital in Shanghai. He later transitioned into the industry, where he held senior roles across clinical and business development, including as global vice-president of IQVIA Holdings Inc., and as the founder and chief executive officer of Shanghai PPC Biopharmaceutical Technology. Zhu first joined Henlius in January 2021 as a senior vice president and chief medical officer; he rose to president 11 months later and has been CEO since July 2023.
Henlius – which takes its name from an early founder and a Greek god – has benefitted from the sale of drugs that can treat mainstream cancers -- breast, lung, and gastrointestinal. Cancer incidence in both China and overseas is expected to rise due to gaining populations, environmental exposure and lifestyle changes, Zhu noted. China and the U.S. along account for about 40% of the world's cancer cases. Though cancer is traditionally treated through chemotherapy, radiology or surgical removal, newer biologic medicine offers a more precise approach, such as targeting the cancer cells through the body's immune system.
The global rise of cancer illustrates the universality of many diseases and why internationalization is a natural course for many pharmaceutical companies able to offer treatments, said Zhu. The marginal cost of expanding a drug to new global markets is relatively low once development is complete, but the commercial upside is exponential, he said. One treatment can be licensed as dozens of branded products globally under different distributors. Zhu believes the company's most promising pipeline drug is HLX43, a novel, cancer-fighting PD-L1 antibody-drug conjugate, Zhu said. 'HLX43 exemplifies Henlius's next-generation innovation strategy—combining immune checkpoint blockade with targeted cytotoxic delivery to enhance anti-tumor efficacy while minimizing off-target effects,' he said.
To boost its international business, Henlius will increase investment in its international commercial teams, transitioning from out-licensing to self-marketing, buoyed by innovation, Zhu said. 'The U.S. has long known for innovation, while companies in China are now better at industrialization,' says Zhu. Henlius's leader wants to 'combine innovation with this knack of industrialization. Innovation can be described as doing something abnormal. Innovation means you want to do things differently and push beyond established forms.'
Investigators and global collaborators gathered at the Henlius reception during the annual meeting ... More of the American Society of Clinical Oncology held in Chicago May 30-June 3 this year. Shanghai Henlius
To be sure, geopolitical tensions this year are hard to ignore. 'While geopolitical tensions may present uncertainties, we believe high-quality, life-saving treatments will continue to find their place globally.'
In Asia, Henlius is expanding its investment and talent; Japan is a strategic market where Henlius opened a wholly owned subsidiary this year. There, Henlius is exploring 'hybrid go-to-market' models and working to advance drug candidates to fight gastric and small cell lung cancer, among other illnesses. 'This move is part of Henlius's broader globalization strategy to expand its international footprint with end-to-end capabilities—from clinical development and regulatory filing to market access and commercialization,' Zhu said.
Emerging markets like the Middle East offer high growth and less competition, Zhu believes. In Latin America, Henlius partners with leading local companies to distribute treatments throughout the region. The company has conducted international clinical development trials in the U.S., EU, Australia, Southeast Asia, and Japan. Its commercial partnerships with over 20 global firms, including Accord, Abbott, Eurofarma, Organon, and Sandoz. Sandoz just this year agreed to pay Henlius $31 million as part of a licensing agreement that involved a biosimilar HLX13.
Shareholders investors optimistic about Zhu's leadership and Henlius's growth prospects rejected a privatization offer by Fosun Pharmaceutical earlier this year for HK$24.60 share. Does the subsequent big increase in its share price augur a new round of capital-raising? 'Henlius maintains a disciplined approach to capital strategy. While the company is currently well-capitalized, it remains open to strategic financing opportunities that could accelerate global R&D programs or support entry into new markets. Any fundraising plans would align with shareholder value creation,' Zhu said.
A physician who worked closely for years with ill patients, Zhu reflected in a personal way how business decision-making can similarly be difficult. 'We cannot do everything. Sometimes we have to say no to our heart. Every year I have to say no over 50 times. During the development process, if we're not 100% confident about identifying the right differentiators to address patient needs then we regretfully have to say, 'Sorry, I cannot move you along to the next stage.''
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Huawei's AI Scandal Just Exploded--And Investors Should Be Paying Attention
Huawei is pushing backhard. Over the weekend, its secretive Noah's Ark Lab broke from its usual silence to address accusations that its new AI model, Pangu Pro MoE, borrowed code without proper credit. The model, which runs on Huawei's own Ascend chips (their homegrown answer to Nvidia's GPUs), had its source code picked apart on GitHub, where a group dubbed HonestAGI claimed it spotted unacknowledged code fragments. That post vanished. But another one, titled Pangu's Sorrow, quickly followedalleging that Huawei's team had been under intense pressure to deliver and fell behind domestic rivals in the race. In a rare rebuttal, Huawei said it fully complied with open-source licenses and welcomed technical discussion, not speculation. This isn't just a code reviewit's a window into the internal pressure mounting inside China's AI champions. With Alibaba and DeepSeek making waves and catching investor attention, Huawei's rare public statement signals how high the stakes are becoming. The companylong a symbol of China's tech self-sufficiencynow finds itself on the defensive in one of the hottest battlegrounds: sovereign AI. The fact that Huawei had to respond at all speaks volumes. IP compliance, innovation speed, and trust are no longer soft issuesthey're table stakes in an environment where reputations are earned (or lost) in public. For global investors watching the AI value chainfrom chipmakers like Nvidia (NASDAQ:NVDA) to downstream platforms like Tesla (NASDAQ:TSLA)this is another flashing signal. The game isn't just about who builds the fastest model. It's also about who's playing fair, who's shipping on time, and who's earning credibility in a world that increasingly demands transparency. As China's AI ecosystem matures, these reputational battles could become just as important as the hardware wars. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
21 minutes ago
- Yahoo
CPER Sinks as China, Dollar Tariffs Weigh on Copper
The United States Copper Index Fund (CPER), a popular way for investors to gain exposure to the industrial metal, finds itself down from a range of negative forces, as the exchange-traded fund sank more than 2% in Monday afternoon trading. This recent dip in spot copper prices, which began July 3, comes after a period of robust performance, leaving many to wonder about the immediate future for the bellwether commodity. The current weakness in copper can be attributed to a confluence of factors, including resurfacing trade tensions, a notable buildup in inventories and a softening of short-term demand. Several immediate catalysts are contributing to the recent downtrend in copper prices, weighing on the CPER ETF, which tracks copper futures contracts and provides convenient access to the metal's price movements. Renewed tariff tensions and heightened trade policy uncertainty are casting a long shadow. Reports suggest that the looming prospect of U.S. tariffs, with deadlines approaching, is causing industrial players to exercise caution, potentially leading to reduced inventory accumulation and a deferral of capital expenditures. This "wait-and-see" approach translates directly into a temporary slowdown in demand for copper. There's been a noticeable increase in global copper inventories, particularly at major Chinese ports. Data indicate a substantial week-over-week rise in nationwide copper inventories in early July. When supply in warehouses grows significantly faster than immediate consumption, it naturally puts downward pressure on prices, regardless of long-term fundamentals. This inventory buildup reflects not only increased import volumes but also a weakening in short-term consumption. While the U.S. dollar has weakened in 2025, it's inched 1% higher since July 3, as copper is primarily traded in U.S. dollars on global markets and a stronger dollar makes the commodity more expensive for international buyers using other currencies. This effectively dampens global demand, contributing to price declines. Recent U.S. economic data, such as robust employment reports, can bolster the dollar, inadvertently putting pressure on dollar-denominated commodities like copper. Despite the current short-term headwinds, the long-term outlook for copper remains overwhelmingly bullish, driven by powerful structural trends. The most significant factor is the global energy transition. Copper is an indispensable component in nearly all green technologies, from electric vehicles (EVs), which use significantly more copper than traditional internal combustion engine vehicles, to renewable energy infrastructure like solar panels and wind turbines. The vast expansion of electrical grids, necessary to support increased electrification and intermittent renewable energy sources, also demands colossal amounts of copper. Furthermore, the burgeoning demand from data centers to power artificial intelligence infrastructure represents another rapidly growing area of copper consumption. Beyond demand, the supply side faces inherent constraints. Developing new copper mines is a capital-intensive, time-consuming process, with lead times from discovery to production often stretching well over a decade. The recent decline in spot copper prices, reflected in ETFs like CPER, highlights the inherent volatility of commodity markets. While immediate factors such as trade uncertainty, inventory surges and seasonal demand weakness are influencing the current pullback, investors should remember that the industrial metal is also supported by powerful, long-term secular growth drivers. As with any metal or commodity investment, understanding both the short-term catalysts and the long-term fundamentals while recognizing the speculative nature of spot prices is crucial for making informed investment decisions. Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investing in ETFs involves risks, and investors should carefully consider their investment objectives and risk tolerance before making any investment decisions. At the time of publication, Kent Thune did not hold a position in any of the aforementioned | © Copyright 2025 All rights reserved


Bloomberg
22 minutes ago
- Bloomberg
Japan Stocks Set to Follow Yen Lower After New Tariff Deadline
Japanese equities were poised join the yen in moving lower as investors in Tokyo awoke on Tuesday to weeks of more uncertainty over US tariffs. The currency dropped more than 1% versus the dollar during the New York session overnight while the American depositary receipts of Japanese companies traded in the US slid after President Donald Trump wrote a letter to Prime Minister Shigeru Ishiba threatening levies of 25% beginning Aug. 1.